Mp60-05 Myb Exhibits Racially Disparate Expression and Clinicopathologic Association and Is a Promising Predictor of Biochemical Recurrence in Prostate Cancer

You have accessJournal of UrologyProstate Cancer: Advanced (Including Drug Therapy) III (MP60) 1 May 2024MP60-05 MYB EXHIBITS RACIALLY DISPARATE EXPRESSION AND CLINICOPATHOLOGIC ASSOCIATION AND IS A PROMISING PREDICTOR OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER Mohammad A. Khan, Sriian Acharya, Naden Kreitz, Shashi Anand, Fnu Sameeta, Paramahansa Pramanik, Christopher Keel, Seema Singh, James Carter, Santanu Dasgupta, and Ajay Singh Mohammad A. KhanMohammad A. Khan, Sriian AcharyaSriian Acharya, Naden KreitzNaden Kreitz, Shashi AnandShashi Anand, Fnu SameetaFnu Sameeta, Paramahansa PramanikParamahansa Pramanik, Christopher KeelChristopher Keel, Seema SinghSeema Singh, James CarterJames Carter, Santanu DasguptaSantanu Dasgupta, and Ajay SinghAjay Singh View All Author Informationhttps: //doi. org/10. 1097/01. JU. 0001008804. 84010. ec. 05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We recently identified MYB, a proto-oncogene encoding a transcription factor protein, as a potentiator of prostate cancer (PCa) aggressiveness and castration-resistance through aberrant activation of androgen-receptor (AR) signaling. PCa is the most common malignancy of the urinary tract exhibiting significant race-associated health disparities. Black/African American (AA) men have 70% more chances of being diagnosed with PCa and are over twice more likely to die because of this malignancy than their White/Caucasian American (CA) counterparts. Radical prostatectomy and radiation therapy are the most common choice of treatment for localized PCa patients, yet nearly 20-40% PCa patients experience eventual disease relapse (5). Patients with locally advanced or metastatic disease receive androgen-deprivation or castration therapy (ADT/CT) as primary line of treatment but disease relapse is inevitable in nearly all patients sooner or later after an initial response. The goal of this study was to examine MYB expression in prostate tumors from patients of different racial backgrounds and study its clinicopathological association. METHODS: A total of 105 PCa cases White (n=50) and Black (n=55) with available clinicopathologic data were procured. Immunohistochemical analysis was performed to analyze MYB and AR expression in PCa, adjacent benign prostatic hyperplasia (BPH) and high-grade prostatic intraepithelial neoplasia (HGPIN). Stained slides were scanned and digitally analyzed for the measurement of percent positivity (0-100%) and staining intensity (1+, 2+ and 3+). A cumulative H score was calculated by multiplying this value with percent positive cells for each staining intensity 1x (% positive cells with 1+staining) + (2x (% positive cells with 2+ staining) }+ (3x (% positive cells with 3+ staining) }. Mann Whitney U or Kruskal-Wallis tests were used for comparing two or multiple groups, respectively. Pearson's correlation was examined to study the correlation of MYB with different factors. RESULTS: MYB is overexpressed in PCa exhibiting negligible expression in BPH. Aberrant MYB expression starts early in HGPIN and increases progressively, correlating with advancing tumor grades. PCa tissues from Black patients display higher MYB expression than White patients in overall and grade-wise comparisons. MYB also shows a positive correlation with AR expression and both display higher expression in advanced tumor stages. Notably, we find that MYB is a better predictor of biochemical recurrence than AR, pre-treatment PSA, or Gleason's grades. CONCLUSIONS: Our findings establish MYB as a promising molecular target in PCa that could be exploited for improved risk prediction, therapeutic planning, and as a novel therapeutic vulnerability to treat castration-resistant PCa. Source of Funding: None © 2024 by American Urological Association Education and Research, Inc. FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e1000 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc. Metrics Author Information Mohammad A. Khan More articles by this author Sriian Acharya More articles by this author Naden Kreitz More articles by this author Shashi Anand More articles by this author Fnu Sameeta More articles by this author Paramahansa Pramanik More articles by this author Christopher Keel More articles by this author Seema Singh More articles by this author James Carter More articles by this author Santanu Dasgupta More articles by this author Ajay Singh More articles by this author Expand All Advertisement PDF downloadLoading. . .